Evidence, Interpretation, and Qualification From Multiple Reports of Long- Term Outcomes in the Multimodal Treatment Study of Children With ADHD (MTA), Part I: Executive Summary by Swanson, James et al.
Journal of Attention Disorders Vol. 12(1):4-14 (2008) 
ISSN: 1087-0547 
doi:10.1177/1087054708319345 
This is a peer reviewed pre-print version of the following article: Evidence, Interpretation, and Qualification From 
Multiple Reports of Long-Term Outcomes in the Multimodal Treatment Study of Children With ADHD (MTA), 
Part I: Executive Summary, which has been published in final form at: 
http://www.sagepub.com/home.nav 
http://jad.sagepub.com/ 
http://jad.sagepub.com/content/12/1/4.full.pdf+html 
© 2008 Sage Publications Ltd. 
Evidence, Interpretation, and Qualification From Multiple Reports of Long-
Term Outcomes in the Multimodal Treatment Study of Children With ADHD 
(MTA), Part I: Executive Summary 
James Swanson, L. Eugene Arnold, Helena Kraemer, Lily Hechtman, Brooke 
Molina, Stephen Hinshaw, Benedetto Vitiello, Peter Jensen, Ken Steinhoff, Marc 
Lerner, Laurence Greenhill, Howard Abikoff, Karen Wells, Jeffery Epstein, Glen 
Elliott, Jeffrey Newcorn, Betsy Hoza, and Timothy Wigal (MTA Cooperative Group) 
Objective: 
To review the primary and secondary findings from the Multimodal Treatment study of ADHD 
(MTA) published over the past decade as three sets of articles. 
Method:  
In a two-part article—Part I: Executive Summary (without distracting details) and Part II: 
Supporting Details (with additional background and detail required by the complexity of the MTA)—we 
address confusion and controversy about the findings. 
Results: 
We discuss the basic features of the gold standard used to produce scientific evidence, the 
randomized clinical trial, for which was used to contrast four treatment conditions: medication management 
alone (MedMgt), behavior therapy alone (Beh), the combination of these two (Comb), and a community 
comparison of treatment “as usual” (CC). For each of the three assessment points we review three areas 
that we believe are important for appreciation of the findings: definition of evidence from the MTA, 
interpretation of the serial presentations of findings at each assessment point with a different definition of 
long-term, and qualification of the interim conclusions about long-term effects of treatments for ADHD. 
Conclusion: 
We discuss the possible clinical relevance of the MTA and present some practical suggestions 
based on current knowledge and uncertainties facing families, clinicians, and investigators regarding the 
long-term use of stimulant medication and behavioral therapy in the treatment of children with ADHD. (J. 
of Att. Dis. 2008; 12(1) 4-14) 
A. Introduction and Purpose of Part I (Executive Summary) 
1. Introduction 
The main findings from the Multimodal Treatment study of ADHD (MTA) are described 
in eight articles published over the past decade. The first two articles were published in the 
Archives of General Psychiatry about the 14-month treatment phase (MTA Cooperative Group, 
1999a, 1999b); the next two articles in Pediatrics about the initial 10-month follow-up phase 
(MTA Cooperative Group, 2004a, 2004b); and the most recent four articles in the Journal of the 
American Academy of Child and Adolescent Psychiatry about the subsequent 12-month follow-
up phase (Jensen et al., 2007; Swanson, Elliott, et al., 2007; Swanson, Hinshaw, et al., 2007; 
Molina et al., 2007). The serial reports of complex findings in different journals may make it 
difficult for readers to integrate the main findings, partly because a summary of the information 
is not accessible in one place. Therefore, one of our main objectives is to review and integrate 
the findings from these three sets of articles and make this information accessible to those 
interested in the MTA. 
We will use the terms “primary” and “secondary” to distinguish the articles within each 
set. The first, or primary, article in each set presents the findings (up to a point in time) based on 
the logic and methodology of our randomized clinical trial (RCT) design and narrowly focused 
and rigorous intent-to-treat (ITT) method of analysis. A defining feature of the RCT approach is 
random assignment of participants to treatment conditions, and a defining feature of the ITT 
approach is the evaluation of all participants randomized and assigned to the well-defined 
treatments whether or not they were accepted or implemented as planned. We consider the 
findings from the primary articles based on RCT principles and ITT analyses to represent the 
scientific evidence from the MTA. The next, or secondary, article in each set presents 
interpretations of findings based on a variety of sophisticated and often complicated analyses that 
supplement the primary analyses. These include the systematic explorations of mediators and 
moderators of treatment effects and the evaluation of transition of the RCT into an observational 
follow-up study, which introduces additional conceptual and statistical issues for consideration. 
These should be distinguished from the many additional articles that we have published (see the 
appendix to Part II) using exploratory analyses to suggest possible qualification to the primary 
and secondary findings. We believe these articles have advanced our knowledge about treatment 
of ADHD, but we realize they may have also contributed to confusion and controversy, since the 
varied purposes of these additional articles were to suggest many possible qualifications about 
the findings reported in the primary and secondary articles of the MTA. 
We believe that discussion of the findings from the MTA should be based on a firm 
understanding and appreciation of the strengths and limitations of the design and methods that 
are presented and described in the primary and secondary articles. We hope to dispel some 
confusion and resolve some controversies by a thorough but focused review of these eight main 
articles. This should provide the factual basis for evidence-based interpretations of some of the 
current uncertainties facing families, clinicians, and investigators about the long term use of 
stimulant medication and behavioral therapy for treatment of children with ADHD. 
2. Purpose 
After each main set of publications, questions should be expected about the interim 
findings of a large, publicly funded, national study that is still in progress. Even among MTA 
investigators, there has been open discussion of differences in opinion about emphasis, 
importance, and interpretation of the initial and follow-up findings, and commentaries with a 
variety of viewpoints have appeared in scientific journals as well as in popular media. Because 
discussion of this is a valuable part of the dissemination of findings, our primary purpose is to 
identify some relevant issues about the evidence, interpretation, and qualification of the findings 
that will help address some of the confusion and controversies about the MTA findings through 
the 36-month assessment. 
Integrating the main findings of this very complex series of reports is not a simple task. Our first 
attempt was too long and detailed, so we separated it into two parts. Here in the first part (the 
Executive Summary), we highlight a few key aspects of the three sets of articles, and in the 
second part (Supporting Details) we will provide further explanations and discussions that are 
important but heavy with excruciating detail. In parallel sections of these two articles, for each of 
the three sets of publications we will (a) define what we consider to be evidence from the MTA, 
(b) address confusion and controversies that have been generated by some interpretations of the 
primary and secondary findings the MTA, and (c) discuss what we consider to be important 
qualifications suggested by additional articles intended to supplement the evidence presented in 
the primary articles of the MTA. 
3. Background 
Confusion and controversy might be anticipated from a groundbreaking project as 
complex as the MTA. One layer of complexity is related to the multiple articles in each of the 
three sets of publications (i.e., the eight main articles). We will review the findings from each of 
the three sets of publications in sections here linked to sections in Part II where additional details 
are provided about the methods of the MTA. For example, in the parallel background section in 
Part II, we provide additional details about the following methodological topics: (a) genesis of 
the MTA, (b) design and analysis framework, (c) number, intensity, and duration of treatments, 
(d) randomization and selection bias, (e) multiple outcome measures, (f) multiple comparisons, 
(g) adjustment of significance level, (h) multiple definitions of long term, and (i) a priori and 
post hoc tests. 
B. Publications at the End of Treatment (MTA Cooperative Group, 1999a, 1999b) 
1. Evidence: ITT Analyses 
The design of the MTA was based on the principles underlying the RCT approach, which 
require that participants be randomly assigned to the four treatment conditions: medication 
management alone (MedMgt), behavior therapy alone (Beh), the multimodal combination of 
these unimodal treatments (Comb), and treatment “as usual” in the community (CC). Random 
assignment ensures that the formation of groups is not biased by preferences of those providing 
or receiving the treatments or by other factors that may operate intentionally or unintentionally. 
If the sample size is large enough, randomization should produce groups that do not differ in any 
systematic way at the baseline assessment. The primary analyses of the MTA were based on the 
ITT approach. This is intended to evaluate the effect of assigned rather than actual treatment. 
Actual treatment depends on whether the assigned treatments are accepted and implemented as 
intended. Even if they are not, the primary ITT analyses do not take this into account, although 
secondary analyses may do so. 
The RCT and ITT principles governed the primary analyses of outcomes through the 14-
month assessment that produced the initial evidence from the study. We used omnibus tests of 
treatment by time interactions for multiple outcome measures, followed by multiple pairwise 
comparisons for 10 outcome measures that showed overall significance. This revealed that 
multimodal combination (Comb) was not better than medication management alone (MedMgt) 
on any of these, that MedMgt was better than behavior therapy alone (Beh) on 3 of them, and 
that community comparison (CC) was worse than Comb on 9, MedMgt on 5, and Beh on none of 
them. 
These analyses reveal two key findings (see MTA Cooperative Group, 1999a). First, 
assignment to treatment according to the intensive MTA medication algorithm (MedMgt) 
produced larger benefits (i.e., reduction in ratings of ADHD symptom severity) than assignment 
to treatment according to the intensive MTA behavior therapy algorithm (Beh). Second, relative 
benefit from assignment to the multimodal combination (Comb) was not significantly greater 
than assignment to the MTA medication algorithm alone (MedMgt). 
This evidence based on RCT design and ITT analyses generated some confusion and 
many controversies, including one based on the interpretation that lack of superiority of the 
multimodal treatment over medication alone indicated that the intensive behavior therapy 
provided by the MTA was ineffective. We addressed this erroneous interpretation in secondary 
analyses. 
2. Interpretation: Moderator and Mediator Analyses 
Our secondary moderator and mediator analyses were intended to explore whether 
enhanced response may occur in subgroups and, if so, why this may occur. The findings from 
these analyses are intended to generate hypotheses for future studies based on speculations on 
why treatment effects may be enhanced in some cases (the purpose of moderator analyses) or 
when implemented in particular ways (the purpose of mediator analyses). These exploratory 
analyses appeal to practical interests of clinicians and encourage speculation about broader 
questions than those addressed by our narrowly focused primary analyses. Understandably, this 
may have generated confusion and controversies about the initial findings of the MTA. 
We used moderator analyses to search for baseline variables that might identify which 
participants are likely to have a better response to one treatment than to another. For example, for 
subgroups defined by socioeconomic status, Comb was statistically superior to MedMgt for the 
families on public assistance but not for the others with greater family resources, and for 
subgroups defined by comorbid anxiety, Comb was superior to MedMgt alone (and MedMgt was 
not significantly better than Beh) for children with comorbid anxiety but not for those without 
symptoms of anxiety. The moderator analyses have obvious limitations. For example, the use of 
subgroups increases the number of comparisons that are possible (thus increasing the false-
positive probability) and also decreases the sample size for each comparison (thus increasing the 
false-negative probability). We should point out that statistical significance in one subgroup and 
not in the other does not prove that the interaction is significant (i.e., that the effect size is 
statistically different between the two subgroups).We used mediator analyses to search for a 
change or event that happened during the treatment phase that was correlated with the assigned 
treatment that may explain all of part of the treatment effect on outcome. This led us to evaluate 
how treatments are implemented (i.e., acceptance and attendance related to treatment deemed to 
be “as-intended” or “below-intended”) and to explore how differences that emerged after 
randomization (i.e., during the course of treatment) might affect outcome. For example, as-
intended attendance at the monthly clinic visits during the treatment phase produced better 
outcome than below-intended attendance, and the adjustments of dose of medication at these 
visits were different for the Comb and MedMgt groups. By the 14-month assessment point, the 
Comb group was being treated with a 20% lower dose of medication than the MedMgt group, 
suggesting that compared to MedMgt, the addition of behavioral treatment in the Comb 
treatment contributed to the attainment of the same or better results with a lower dose. 
3. Qualification 
Based on the guidelines of the RCT logic and methodology, our primary ITT analyses 
were narrowly focused on a few main hypotheses, and the results provide the basic evidence 
from the MTA (see above). In secondary and many additional articles (see the appendix to Part 
II), we reported exploratory analyses to supplement the evidence from the primary analyses. In 
Part II, we provide details about the following topics: (a) additional moderator analyses, (b) 
multiple comparisons across outcome domains, (c) single composite outcome measures, (d) 
evaluation of non-ADHD outcome domains, (e) acceptance of the null hypothesis, (f) 
commentaries on the end of treatment findings, and (g) the main confusions and controversies at 
the end of treatment. We will highlight some of these topics here. 
We addressed some methodological issues related to the use of multiple outcome 
measures (i.e., precision of measurement of outcome by any one measure and adjustment of 
significance level for any one statistical test in order to maintain the nominal significance level 
across the multiple tests). We explored the use of single outcome measures to increase precision 
of measurement by compositing multiple measures and to reduce adjustment of the significance 
level. This was intended to overcome some of the consequences of using multiple outcome 
measures that may have contributed to lack of statistical significance between treatments. In 
these articles, we followed the advice of our statistical advisors and focused on estimation of 
effect sizes rather than tests of statistical significance, but they did show significant superiority 
of Comb over MedMgt alone on the composite measures (by effect size d of .26–.28). 
Commentaries about these initial findings of the MTA addressed areas of strength (e.g., 
large sample, RCT design, successful implementation, and sophisticated analyses) and limitation 
(the definition of long term, the nature of “as usual” treatment, the lack of statistical significance 
and acceptance of null hypotheses, the use of high-intensity treatments to evaluate efficacy rather 
than available treatment to address effectiveness, the lack of a placebo control or blind observers, 
the differences between assigned and actual treatment, and others). We will mention a few 
important commentaries here that we consider to be controversial and may be based on 
confusion about the primary findings. 
One controversial interpretation of the initial findings was that behavioral treatment was 
ineffective, which may be due to confusion about relative versus absolute effects in the MTA. In 
the primary article, the effects of treatment were evaluated by comparison of conditions (relative 
effects), which were superimposed on a trend of general improvement over time. The first 
sentence in the discussion section (see MTA Cooperative Group, 1999a) stated that all 4 groups 
showed marked improvement over time. However, we did not fully explain the obvious overall 
effect of time, since this could be due to the treatment or to many other unidentified factors (e.g., 
regression to the mean, expectation effects, secular trends, etc.). This may have contributed to 
confusion. Instead, we emphasized the interaction of two factors in the regression analysis 
(treatment and time), and explained why we made this a precondition to be met before 
performing multiple comparisons of outcomes at the end of treatment phase to contrast 
treatments and estimate relative benefits. A related controversial interpretation of the initial 
findings was that multimodal treatment lacked superiority over unimodal treatment with 
medication, which may be due to confusion about accepting a null hypothesis based on the 
primary ITT analysis. Our statistical consultants warned us that “the absence of evidence should 
not be taken as evidence of absence,” and we believe that when this wise counsel is not heeded 
confusion and controversy should be expected, since non-significance cannot be interpreted 
correctly based on the MTA design and analysis as showing equivalence of the assigned 
treatments. 
C. Publications After the First Follow-Up (MTA Cooperative Group, 2004a, 2004b) 
1. Evidence: ITT Analyses 
In the primary analyses of outcomes from the 24-month assessment (MTA Cooperative 
Group, 2004a), we still used the principles of RCT design and ITT analysis. We did this even 
though the outcomes evaluated were beyond the end of the treatment phase of the MTA protocol 
and 10-months after we made individualized recommendations for participants to seek out 
various clinical services offered in the community. Because the logic and purpose of the RCT 
approach is to evaluate the long-term consequences of assignment to treatment rather than actual 
treatment, the use of ITT analysis to produce the primary evidence of the MTA is appropriate 
even for the followup phase, although it may seem counterintuitive to some. In an observational 
study such as the MTA follow-up, any observed differences between groups may be due at least 
in part to factors that influenced which treatments participants selected to get. In the MTA, 
starting and stopping medication would result in a cross over in terms of actual treatment. So, in 
the MTA as in any RCT of a chronic condition, when followed naturalistically over time, in the 
post-treatment phase almost inevitably there is attenuation of effect due to cross-over and 
heterogeneity of choice within each of the treatment groups. 
The narrowly focused ITT analyses revealed a significant effect of the relative impact of 
assigned treatment on severity of ADHD symptoms (p < .0001) at the 24- month assessment. 
Further comparisons revealed this was because of a persisting relative superiority of the 
treatments that included assignment to the MTA medication algorithm (Comb and MedMgt) over 
those that did not (Beh and CC). The magnitude of this comparison of the assigned treatments 
was reduced by 50% from a moderate effect size (0.6) in the end-of-treatment analyses to a small 
effect size (0.3) in the follow-up analyses. In the primary article (MTA Cooperative Group, 
2004a), current treatment was used as a covariate, and this revealed that across the assigned 
groups, the participants taking medication at the 24-month assessment point had better outcome 
than those not taking medication. This was interpreted as an indication that the apparent 
reduction of the relative superiority of assignment to the MTA medication algorithm (superiority 
of Comb and MedMgt over Beh and CC) may reflect the lack of maintenance of an effective 
intervention more than reduction in the effects of medication during the first follow-up phase of 
the MTA. 
The hypothesis of stimulant-related growth suppression had not been evaluated at the end 
of the treatment phase, so in the first follow-up report (MTA Cooperative Group, 2004b) we 
provided ITT analyses of measures of physical size at the 14-month assessment point. Thus, in 
our terminology, this might be considered a primary analysis, despite its delayed and post hoc 
status. These analyses revealed that the two groups assigned to the MTA medication algorithm 
had slower growth (i.e., gains of 4.85 cm and 2.53 kg for Comb and 4.25 cm and 1.64 kg for 
MedMgt) compared to the other two groups (i.e., gains of 6.19 cm and 4.53 kg for Beh and 5.68 
cm and 3.13 kg for CC). This represented stimulant-related growth suppression of about 23% in 
height gain and 47% in weight gain. However, the ITT analysis of growth during the 10-month 
follow-up revealed the assigned groups did not differ significantly in gain in height or weight 
(Comb = 5.69 cm and 5.28 kg; MedMgt = 5.69 cm and 5.06 kg; Beh = 6.16 cm and 4.98 kg; CC 
= 5.79 cm and 4.58 kg). The slight reduced gain in height for the Comb and MedMgt groups 
provided evidence that there was no growth acceleration (rebound) compared to the Beh and CC 
groups during the 10-month follow-up. 
The extension of the RCT logic and methodology and the use of ITT analyses beyond the 
treatment phase may have resulted in additional confusion and controversies, including one that 
suggested the balance of benefits and side effects was different than expected in the literature, 
with smaller benefits and greater side effects. We addressed this possibility in secondary 
analyses. 
2. Interpretation: Naturalistic Subgroup and Physical Growth Analysis 
In the secondary article (MTA Cooperative Group, 2004b), we explored the effects of 
actual treatment to supplement the analyses of assigned treatment. We explored the use of 14- to 
24-month change scores to supplement the primary analyses that evaluated absolute scores at the 
24-month assessment point. For these analyses, we formed naturalistic subgroups based on 
information about actual treatment at the two assessment points (during the 30 days before the 
14-month and 24-month assessments). This identified four patterns of treatment over time for 
those participants who reported consistent use of medication, no use of medication, stopping 
medication, or starting medication during the follow-up interval. These subgroups were used to 
evaluate the mediating effect of patterns of treatment over time on efficacy (i.e., ratings of 
ADHD symptom severity). In the secondary article, an ITT analyses of change scores confirmed 
that the MTA medication algorithm was associated with deterioration rather than further benefit. 
Then, a mediator analyses based on the naturalistic subgroups confirmed that the reduction in 
longterm superiority of the Comb and MedMgt groups relative to the Beh and CC groups may 
reflect changes in actual use of medication (i.e., lack of maintenance), reflected in the pattern of 
treatment over time. 
One of the main purposes of the secondary article (MTA Cooperative Group, 2004b) was 
to evaluate whether there were changes in growth velocity during the 14- to 24-month follow-up. 
As described above, the 24-month ITT analyses revealed that all assigned groups had about the 
same gain in height during the follow-up interval, suggesting a transitory growth-suppression 
effect. However, mediator analyses based on our naturalistic subgroups revealed that height and 
weight gains were less in the always-treated subgroup (4.53 cm and 3.18 kg) than in the never-
treated subgroup (5.40 cm and 4.83 kg). A comparison of these patterns suggested that stimulant- 
related height suppression continued at the same rate (about 1 cm/year reduction in height gain) 
during the second year when treatment with medication was maintained, but the rate of weight 
suppression was less (about 1.2 kg/year reduction in weight gain). 
3. Qualification 
Issues about the impact of changes in the assigned treatments (i.e., starting and stopping 
medication), which appeared to be relevant for outcome measures related to efficacy (ADHD 
ratings) and to side effects (height and weight gain), were addressed in both the primary and 
secondary articles. Multiple exploratory approaches were used to evaluate some obvious 
hypotheses about persistence and desistance of both efficacy (e.g., reduction of ADHD symptom 
severity) and side effects (stimulant- related growth suppression). In Part II, we provide 
additional details about two topics: (a) partial loss of relative benefits of medication and (b) the 
main confusions and controversies at the first follow-up. 
Even in the primary article (MTA Cooperative Group, 2004a), mediator analyses were 
performed to evaluate how changes in medication use between the 14- and 24- month assessment 
points might have affected outcomes. At the 14-month assessment, compliance with assigned 
medication use was high (87% and 93%) in the Comb and MedMgt groups, but this decreased by 
the 24-month assessment (to 70% and 72%). In contrast, in the Beh and CC groups, the 
percentage of participants with medication use increased from 23% and 55% at the 14-month 
assessment to 38% and 62% by the 24-month assessment. By adding a covariate (interim 
medication use) in the ITT analyses, we documented that the effect of current medication use 
was statistically significant. This suggested that the reduction in relative superiority of the MTA 
medication algorithm for symptomatic improvement was related to lack of maintenance of 
medication. However, even when adjusted for the beneficial effects of current medication use, 
the effect of assigned treatment was still significant. This indicated that the persisting effect of 
the relative superiority of assignment to the Comb and MedMgt conditions versus the Beh or CC 
conditions was not entirely dependent on continuing the use of medication (i.e., that there might 
be a positive “carry-over” effect even when medication use was stopped). 
This pattern was confirmed in the secondary article, which evaluated 14- to 24-month 
change scores. The participants who stopped medication deteriorated, whereas those who started 
medication improved during the 10- month follow-up. Based on this, we speculated that the 
patterns of actual treatment that emerge over time may explain most of the observed partial loss 
of the relative benefits of initial assignment to the MTA medication algorithm. We also predicted 
that if this trend of actual use of medication continued, then eventually there would be a 
complete loss of the effect of assigned treatment evaluated by ITT analysis. 
The analyses of side effects at the 24-month assessment point suggested that the growth 
suppression effect was attenuated, and the contrast of assigned groups was no longer statistically 
significant. This suggests that differential treatment effects on growth dissipated during 
followup. However, there was no evidence of growth rebound in the Comb and MedMgt groups 
relative to the Beh and CC groups during the 10-month follow-up (i.e., there was no “catch-up”). 
Also, a mediator analysis was performed based on subgroups defined by patterns of actual 
treatment over time. This exploratory analysis suggested that the participants who were 
continuously medicated showed slower growth compared to those who were not medicated, 
suggesting that stimulant-related growth suppression may continue when treatment is 
maintained. 
Thus, at this point in the MTA follow-up (at the 24- month assessment), both the primary 
and secondary articles suggested that the outcomes over time depended on maintenance of 
treatment with medication and actual treatment patterns. This held for measures of long-term 
efficacy (reduction of severity of symptoms) as well as a measure of long-term side effects 
(reduction in height gain). 
D. Second Follow-Up (Jensen et al., 2007; Swanson, Elliott, et al., 2007; Swanson, Hinshaw, 
et al., 2007; Molina et al., 2007) 
1. Evidence: ITT Analyses 
The continued use of the RCT logic and methodology again led us to perform narrowly 
focused ITT analyses to evaluate the effects of assigned rather than actual treatment through the 
36-month assessment (Jensen et al., 2007). This primary analysis revealed a further decrease in 
the initial large relative advantage of assigned treatment with stimulant medication on ratings of 
ADHD symptom severity, and by this point in the MTA follow-up, the relative superiority (e.g., 
greater reduction in ADHD symptom severity related to assignment to Comb and MedMgt 
compared to Beh and CC) was completely lost. The ITT analyses indicated that the assigned 
groups did not differ significantly on any of five outcome measures, and a comparison of effect 
size for the most sensitive measures for treatment effects (i.e., a composite of parent and teacher 
ratings of severity just for ADHD symptoms) indicated that the large relative superiority of the 
MTA medication algorithm at the 14-month assessment (.86) was negligible at the 36-month 
assessment (.10). 
We were concerned that the continued use of the RCT approach and ITT analyses might 
create new confusions and controversies, so mediator analyses were reported in the primary 
article (Jensen et al., 2007) to evaluate whether the loss of relative superiority of medication was 
relative to maintenance of treatment, as had been predicted. However, we could not show that the 
loss was due to a further decrease in the percentage of Comb and MedMgt cases using 
medication, which remained about the same at the 24- and 36-month assessments. Instead, 
analysis of 24- to 36-month change in treatment and outcome indicated that continued 
medication use was a marker of deterioration rather than benefit. We addressed this observation 
in secondary analyses. 
2. Interpretation: Multiple Secondary Articles 
After the first follow-up, we hypothesized that a continued loss of relative superiority of 
the Comb and MedMgt groups would be associated with continued decrease in the actual use of 
medication in these groups, but this was not confirmed in the analyses of the second follow-up. 
Instead, the continued loss occurred despite maintenance of about the same level of medication 
use during the second follow-up phase of the MTA. Thus, the long-term follow-up over the 3-
year period suggested that the relative benefits of early use of the intensive medication 
management approach of the MTA might be temporary (i.e., that the initial relative superiority 
may not last forever). Three secondary articles accompanied the primary article to address this 
finding, and we will discuss each of these here (see below). 
Swanson, Hinshaw, et al. (2007) addressed the hypothesis that the loss of relative 
superiority may be due to selection bias (i.e., the selective treatment of the most severe cases, 
which might operate to mask underlying benefits of medication). This was evaluated using the 
propensity score method. Despite the use of this sophisticated statistical method, our findings did 
not support this key hypothesis. Another approach addressed whether individual differences in 
response may have masked beneficial effects of medication. This was evaluated using the 
statistical method of growth mixture model analysis. This complex analysis identified three 
latent classes (subgroups) with different trajectories of outcome (e.g., decreases in ADHD 
symptom severity) over time. In two of the classes, there was a large initial improvement 
(decrease in ratings of ADHD symptoms severity). In one of these (52% of the sample), the large 
initial large improvement was maintained over time, but in the other (14% of the sample), it 
dissipated over time. The trajectory of another class (34% of the sample) was defined by initially 
modest but gradually greater improvement over time. The relative advantage of medication was 
small but significant at the 14-month assessment and then increased over time and remained 
significant at the 36-month assessment. Thus, in this subgroup, those participants taking 
medication fared significantly better than those not taking medication, and the relative benefit 
did not dissipate over time. However, in the other two classes (comprising 66% of the total 
sample), a different pattern was observed. A large and significant medication effect was present 
initially but then did dissipate over time. Apparently, this effect (dissipation of the beneficial 
effects of medication) that characterized most of the participants (66%) overshadowed the 
longterm beneficial effect of medication observed in a smaller subset of participants (34%). 
Swanson, Elliott, et al. (2007) extended the evaluation of patterns of actual medication in 
naturalistic subgroups defined by patterns of treatment over time. Information about treatment 
prior to entry into the MTA as well as during the MTA was used, which provided four time 
points for medication status (at the baseline, 14-month, 24-month, and 36-month assessments). 
This allowed us to establish subgroups for participants who were never treated, always treated 
(even before entering the MTA), newly treated (continuously after entering drug naïve), and 
inconsistently treated (because of starting or stopping) with medication. We hypothesized that 
consistent treatment with medication might result in maintenance of superiority at the 36-month 
assessment. However, this was not confirmed: Our naturalistic subgroups did not differ 
significantly on ADHD symptom-severity at the 36-month assessment. In addition, we 
hypothesized that growth rebound might occur, but this was not observed either. Those whose 
height trajectory had been slowed by medication use did not show further reduction in height 
gain, but they did not “catch up” (i.e., they did not make up the prior less-than-expected height 
gain with a subsequent greater-than-expected height gain). 
Molina et al. (2007) evaluated new outcome domains that become relevant during early 
adolescence, including substance use experimentation and juvenile delinquency. We used ITT 
analyses to test the widely held hypothesis that early treatment with stimulant medication (i.e., 
assignment to the MTA medication algorithm) would provide protection from these adverse 
outcomes during this critical period of development from childhood to adolescence. However, 
the results did not support this hypothesis. Instead, the only statistically significant effect 
suggested protection against early substance use in groups assigned to treatments including the 
MTA behavior therapy algorithm (Comb and Beh) compared to those that did not (MedMgt and 
CC). 
The findings of these secondary articles were not consistent with some expectations about 
medication effects that were generally accepted by many of the field’s investigators and 
clinicians in 2007. That is, long-term benefits from consistent treatment were not documented; 
selection bias was not shown to account for the loss of relative superiority of medication over 
time; there was no evidence for “catch-up” growth; early treatment with medication did not 
protect against later adverse outcomes. We expect that these challenges to the field’s views will 
contribute to future controversies about the long-term outcomes in the MTA. For example, after 
the 14-month treatment phase, all MTA participants received treatment “as usual” in the 
community. We and others have speculated that changes in how treatment with medication was 
managed may have contributed to loss of relative benefits over time. We were not able to 
document this, but it remains as a possibility that should be evaluated in future research. 
3. Qualification: Challenges to Consensus Views and New Predictions 
The set of four articles describing the second followup were published so recently that 
there has not been sufficient time yet for subsequent articles or commentaries to be published. 
Therefore, in this section, we provide some commentary to initiate discussion about what they 
suggest—that is, the lack of long-term effects of past or current treatment with stimulant 
medication. In Part II, we provide additional details about two topics: (a) the main confusions 
and controversies at the second followup and (b) subsequent studies of multimodal treatment of 
children with ADHD. 
First, it is important to express caution about interpretations based on observations of 
nonsignificance of statistical tests. Based on the limitations of the design and methods of the 
MTA, the dangers of acceptance of the null hypothesis should be noted, and additional 
alternative hypotheses should be considered. Second, it is important to remember that the 
evaluation of actual treatment as well as assigned treatment is an important part of the follow-up 
analyses. With these and other cautions in mind, we will point out some qualifications of the 
three secondary articles about outcomes at the 36-month assessment. 
The hypothesis of selection bias cannot be dismissed (Swanson, Hinshaw, et al. 2007) by 
propensity score analysis because the propensity score is based on the finite set of measures we 
established with our MTA battery. Therefore, many other unmeasured factors could be operating 
to mask underlying benefits of treatment with stimulant medication. Also, the use of propensity 
score analyses rests on the assumption that selection biases can be modeled as a simple linear 
combination of multiple variables (e.g., severity of symptoms, previous experience with 
medication, initial treatment response, ethnicity, socioeconomic status, and other variables), and 
this assumption may not hold for the complex baseline measures of the MTA battery. 
The hypothesis of growth rebound cannot be dismissed yet (Swanson, Elliott, et al., 
2007), because it is still possible that rebound may occur during adolescence. This is most 
relevant for height, because weight and body composition are subject to variation at any stage of 
development but height is not. Logically, the hypothesis of growth rebound for height would not 
be adequately evaluated until ultimate height is attained in adulthood. The evaluations at the 36-
month assessment were conducted when most of the MTA participants were between 11 and 13 
years of age. The outcomes at the 12-year assessment (when the participants will be 19 to 21 
years of age) will provide more definitive data to address this important issue. Also, some 
uncertainty about the effects of prior treatment exists, because the largest effect was due to a 
baseline difference between the always- and never-treated subgroups, even though these 
subgroups were established prospectively by patterns of medication use during the MTA. 
Our formation of homogeneous subgroups with growth mixture model analysis was 
based on the limited trajectory of outcome with just four assessment points from baseline 
through the 36-month assessment (Swanson, Hinshaw, et al., 2007). The heterogeneity of 
trajectories in the sample could change during adolescence and into adulthood, so the statistically 
defined subgroups may change in future evaluations of long-term outcome. The reported patterns 
observed so far, with two subgroups (66% of the sample) showing possible decreasing 
effectiveness of medication and one (34% of the sample) showing possible increasing 
effectiveness, may change when outcomes at additional assessment points are included in the 
growth mixture model analyses. Subsequent analyses based on this technique will be able to 
determine whether these patterns continue, or whether different patterns across the same or 
different subgroups emerge when the sample is older and at a more mature stage of development. 
The hypothesis of the protective (or predisposing) effects of early treatment cannot be 
dismissed (Molina et al., 2007) at this time, because it cannot be adequately or fully tested until 
adolescent and adult patterns of substance abuse and dependence emerge to be evaluated. The 
growth mixture model analysis of these outcome measures did not identify heterogeneity of 
trajectories over time, so subgroups were not defined and evaluated as in the growth mixture 
model analysis of the ADHD symptom-severity outcome measure (see above). Based on a 
developmental perspective, this was not unexpected because the range of outcomes on these 
variables is low until adolescence, and some measures of substance use and antisocial behavior 
are not expected to become stable until adulthood. Future analyses will address these 
developmental issues. 
D. Clinical Relevance: Practical Suggestions and Future Directions 
The initial findings of the MTA at the 14-month assessment (MTA Cooperative Group, 
1999a, 1999b) clearly show relative superiority of assignment to the MTA medication algorithm 
on ADHD symptoms. This provides evidence of long-term benefits of stimulant medication for 
over 1 year. This provided an answer to the fundamental question the MTA was designed to 
address. These initial findings were important, because when the MTA was initiated there was 
little information in the literature on the long-term effects of stimulants. 
The findings from the first follow-up provided another contribution to the sparse 
literature on long-term effects of medication. The statistically significant persistence at the 24-
month assessment provides evidence of long-term benefits over 2 years. The observation of 
partial loss of the superiority of assignment to the MTA medication algorithm should be 
interpreted in light of maintenance of treatment, which was reduced in the transition to treatment 
“as usual” in the community and some documented limitations of community medication 
treatment. 
The findings from the second follow-up at the 36- months assessment suggest the 
temporary nature of the superiority of assignment to intensive, carefully monitored medication 
management (i.e., to the MTA medication algorithm), which may gradually dissipate completely 
when the children are returned to community treatment. These interim findings also suggest that 
the relative benefits are not apparent even in subgroups of participants who maintained treatment 
over time (i.e., when comparing the subgroup of participants never treated to the subgroup 
always treated with stimulant medication). 
The findings at successive follow-up phases of the MTA do not contradict the prior 
findings from an earlier phase, but at each step, so far, the findings have provided new 
perspectives to be considered about long-term effects of treatment of children with ADHD. 
In Part II, we provide additional details about the following questions: (a) What is the 
first line treatment for ADHD? (b) Do stimulants suppress physical growth? (c) Does 
recommendation of medication provide long-term benefit? (d) Does maintenance of treatment 
produce maintenance of relative superiority of medication? (e) Does selection bias mask 
beneficial effects of medication? and (f) Do some subgroups benefit more than others? 
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